Evidence map›Paper›PMID 37774953›Full record

ReviewJournal of controlled release : official journal of the Controlled Release Society2023

Experimental and mathematical approaches for drug delivery for the treatment of wet age-related macular degeneration.

Eduardo A Chacin Ruiz, Katelyn E Swindle-Reilly, Ashlee N Ford Versypt

Open access · hybridAbstract readReview
In one paragraph

Review in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Eduardo A Chacin RuizDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA.
Katelyn E Swindle-ReillyWilliam G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH, USA; Department of Biomedical Engineering, The Ohio State University, Columbus, OH, USA; Department of Ophthalmology and Visual Sciences, The Ohio State University, Columbus, OH, USA.
Ashlee N Ford VersyptDepartment of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA; Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, NY, USA; Institute for Artificial Intelligence and Data Science, University at Buffalo, The State University of New York, Buffalo, NY, USA. Electronic address: ashleefv@buffalo.edu.
University at Buffalo, State University of New York · USThe Ohio State University · US

Funding

Quantitative Systems Biomedicine and Pharmacology for Multiscale Tissue DamageR35GM133763 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Ashlee Nicole Ford Versypt · 2019 to 2026
$2.7M
Predictive Drug Release from a Tunable Injectable CapsuleR01EB032870 · NIBIB · OHIO STATE UNIVERSITY · PI Nagaraj Kerur · 2023 to 2026
$2.1M
NIBIB NIH HHS R01 EB032870NIGMS NIH HHS R35 GM133763
6 · The paper itself

Abstract

Several chronic eye diseases affect the posterior segment of the eye. Among them age-related macular degeneration can cause vision loss if left untreated and is one of the leading causes of visual impairment in the world. Most treatments are based on intravitreally injected therapeutics that inhibit the action of vascular endothelial growth factor. However, due to the need for monthly injections, this method is associated with poor patient compliance. To address this problem, numerous drug delivery systems (DDSs) have been developed. This review covers a selection of particulate systems, non-stimuli responsive hydrogels, implants, and composite systems that have been developed in the last few decades. Depending on the type of DDS, polymer material, and preparation method, different mechanical properties and drug release profiles can be achieved. Furthermore, DDS development can be optimized by implementing mathematical modeling of both drug release and pharmacokinetic aspects. Several existing mathematical models for diffusion-controlled, swelling-controlled, and erosion-controlled drug delivery from polymeric systems are summarized. Compartmental and physiologically based models for ocular drug transport and pharmacokinetics that have studied drug concentration profiles after intravitreal delivery or release from a DDS are also reviewed. The coupling of drug release models with ocular pharmacokinetic models can lead to obtaining much more efficient DDSs for the treatment of age-related macular degeneration and other diseases of the posterior segment of the eye.

Indexed as

Vascular Endothelial Growth Factor AWet Macular DegenerationDrug Delivery SystemsHumansHydrogelsIntravitreal InjectionsPolymersHydrogelsPolymersVascular Endothelial Growth Factor ADrug release modelingIntravitreal administrationOcular drug deliveryPharmacokinetics modelingPolymer drug deliveryWet age-related macular degeneration

Identifiers

PMID37774953
PMCPMC10842193
OpenAlexW4387209973

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.